VolitionRx Limited
VNRX- 1M
- -13.0%
VolitionRx Limited in brief
VolitionRx Limited is a listed company in the Diagnostics and Research industry, based in Henderson, Nevada, USA. It was founded in 1998. Its market value was $7 M on 30 October 2026, which makes it the 26,406th largest listed company in the world and the 4,351st largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $23 M. Cameron John Reynolds is its chief executive. Its shares trade under the symbol VNRX (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About VolitionRx Limited
Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests.
Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s response to treatment.
From the company's annual report filed with the US SEC: read the report
VolitionRx Limited timeline
- 1998
- 🏁· approximateFounded
- 1999
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed Volitionrx LtdFormerly Standard Capital Corp.
- 2015
- 🔔· approximateInitial public offering on NYSE
- 2025
- 💰Record revenue of $2 millionFY2025, the highest of the 7 years on record.
Events of VolitionRx Limited from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,264 (Jan 2020) · #3,281 (Jan 2021) · #4,011 (Jan 2022) · #4,002 (Dec 2022) · #4,250 (Jul 2023) · #3,760 (Jan 2024) · #2,266 (Mar 2026) · #4,099 (Aug 2026) · #4,283 (Oct 2026) · #4,354 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.1×
- Price / book
- —
- Free cash flow yield
- -273.8%
- Net margin (TTM)
- -699.7%
- Operating margin
- -1256.6%
- Return on equity
- —
- Liabilities / assets
- 615.8%
- Net debt
- $6M
- Revenue growth
- +40.7%
- R&D / revenue
- 582.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2M | +40.7% | $-22M | $-23M | -1350.3% |
| Dec 2024 | $1M | +57.7% | $-27M | $-27M | -2192.7% |
| Dec 2023 | $1M | +151.6% | $-36M | $-36M | -4574.4% |
| Dec 2022 | $0M | +244.4% | $-32M | $-31M | -9871.0% |
| Dec 2021 | $0M | +800.0% | $-28M | $-27M | -29988.9% |
| Dec 2020 | $0M | -50.0% | $-21M | $-20M | -204000.0% |
| Dec 2019 | $0M | — | $-16M | $-16M | -80500.0% |
| Dec 2018 | — | — | $-18M | $-18M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-20M | $0M | $-20M | — | — |
| Dec 2024 | $-26M | $0M | $-26M | $-0.31 | — |
| Dec 2023 | $-18M | $1M | $-19M | $-0.50 | — |
| Dec 2022 | $-15M | $2M | $-17M | — | — |
| Dec 2021 | $-21M | $1M | $-22M | $-0.51 | — |
| Dec 2020 | $-16M | $2M | $-18M | $-0.45 | — |
| Dec 2019 | $-13M | $1M | $-13M | $-0.41 | — |
| Dec 2018 | $-15M | $-0M | $-14M | $-0.57 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M (+155.6% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportDirectors or officers changed
- Oct 27, 20268-KCurrent reportMaterial agreement · Other events
- Sep 25, 20268-KCurrent reportUnregistered share sale
- Sep 15, 20268-KCurrent reportUnregistered share sale
- Sep 14, 20268-KCurrent reportOther events
- Sep 2, 20268-KCurrent reportMaterial agreement
- Sep 2, 20268-KCurrent reportUnregistered share sale
- Aug 24, 20268-KCurrent reportUnregistered share sale
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
Official filings of VolitionRx Limited with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-22 M
- Net income
- $-23 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $42 M
- Total equity
- $-34 M
As of December-2025
Top 28 institutional investors in VolitionRx Limited#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Lagoda Investment Management, L.P. | 1,669,686 | +213,736 (+14.68%) | 4.63% | $0 M | Nov 16, 2026 |
| 2 | Luminus Management LLC | 425,372 | +268,475 (+171.12%) | 1.18% | $0 M | Nov 16, 2026 |
| 3 | Quadrant Private Wealth Management, LLC | 85,000 | New | 0.24% | $0 M | Nov 4, 2026 |
| 4 | Miller Financial Services LLC | 71,000 | New | 0.20% | $0 M | Oct 20, 2026 |
| 5 | UBS Group AG | 50,867 | +46,448 (+1051.10%) | 0.14% | $0 M | Nov 10, 2026 |
| 6 | Vanguard Capital Management LLC | 50,684 | 0 (0.00%) | 0.14% | $0 M | Nov 13, 2026 |
| 7 | Geode Capital Management, LLC | 50,217 | -5,320 (-9.58%) | 0.14% | $0 M | Nov 6, 2026 |
| 8 | Wealthspire Advisors, LLC | 50,000 | +5,000 (+11.11%) | 0.14% | $0 M | Nov 13, 2026 |
| 9 | Citadel Advisors LLC | 47,656 | New | 0.13% | $0 M | Nov 16, 2026 |
| 10 | Stifel Financial Corp | 45,050 | New | 0.12% | $0 M | Nov 12, 2026 |
| 11 | XTX Topco Ltd | 35,347 | +9,966 (+39.27%) | 0.10% | $0 M | Nov 16, 2026 |
| 12 | State Street Corp | 33,680 | -315 (-0.93%) | 0.09% | $0 M | Nov 12, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 25,133 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 14 | BlackRock, Inc. | 19,087 | -3,221 (-14.44%) | 0.05% | $0 M | Nov 13, 2026 |
| 15 | StoneX Group Inc. | 14,589 | New | 0.04% | $0 M | Nov 3, 2026 |
| 16 | Northern Trust Corp | 12,978 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 17 | Silverberg Bernstein Capital Management LLC | 10,636 | -1,884 (-15.05%) | 0.03% | $0 M | Oct 13, 2026 |
| 18 | Tower Research Capital LLC (TRC) | 5,922 | +154 (+2.67%) | 0.02% | $0 M | Nov 16, 2026 |
| 19 | Northwestern Mutual Wealth Management Co | 1,999 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 20 | SBI Securities Co., Ltd. | 750 | +562 (+298.94%) | 0.00% | $0 M | Oct 22, 2026 |
| 21 | Hickory Point Bank & Trust | 250 | New | 0.00% | $0 M | Oct 1, 2026 |
| 22 | Jones Financial Companies Lllp | 150 | New | 0.00% | $0 M | Nov 13, 2026 |
| 23 | Morgan Stanley | 31 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 24 | Royal Bank Of Canada | 31 | New | 0.00% | $0 M | Nov 16, 2026 |
| 25 | Osaic Holdings, Inc. | 21 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
Show all 28: investors 26 to 28
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Group One Trading LLC | 20 | -2,480 (-99.20%) | 0.00% | $0 M | Nov 10, 2026 |
| 27 | BNP Paribas Financial Markets | 14 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 28 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding VolitionRx Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 31,776 | $0 M | 0.09% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 50,684 | $0 M | 0.14% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,037 | $0 M | 0.02% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 5,775 | $0 M | 0.02% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 588 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at VolitionRx Limited#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ann-Louise BatchelorGroup Chief Marketing Officer | Grant or award | +12,000 | — | — | 27,786 | Form 4 |
| filed | Gaetan MichelChief Operating Officer | Shares withheld for tax | -608 | $0.250 | $152 | 12,232 | Form 4 |
| filed | Gael ForterreChief Commercial Officer | Shares withheld for tax | -284 | $0.250 | $71 | 16,284 | Form 4 |
| filed | Jacob Vincent MicallefChief Scientific Officer | Shares withheld for tax | -5,310 | $0.190 | $1 K | 572,179 | Form 4 |
| filed | Nicholas PlummerGC - Volition Diagnostics | Shares withheld for tax | -7,003 | $0.190 | $1 K | 407,267 | Form 4 |
| filed | Rodney Gerard RootsaertSecretary | Shares withheld for tax | -3,948 | $0.190 | $750 | 273,993 | Form 4 |
| filed | Gael ForterreChief Commercial Officer | Shares withheld for tax | -5,251 | $0.190 | $998 | 331,338 | Form 4 |
| filed | Rodney Gerard RootsaertSecretary | Shares withheld for tax | -3,321 | $0.210 | $697 | 277,941 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: VolitionRx Limited#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2024 | Q4 2024 | $0M |
| Q3 2024 | Q3 2024 | $0M |
| Q2 2024 | Q2 2024 | $0M |
| Q1 2024 | Q1 2024 | $0M |
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q2 2023 | Q2 2023 | $0M |
| Q1 2023 | Q1 2023 | $0M |
| Q4 2022 | Q4 2023 | $0M |
| Q3 2022 | Q3 2023 | $0M |
| Q2 2022 | Q2 2023 | $0M |
| Q1 2022 | Q1 2023 | $0M |
Fails to deliver
- : 42,025 shares at $0.20
- : 469 shares at $0.19
- : 31,836 shares at $0.18
- : 10,857 shares at $0.17
- : 15,377 shares at $0.17
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
VolitionRx Limited scorecard#
Passes 5 of the 15 checks that could be worked out: strongest in growth (4 of 5), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median2.1×Price to sales 2.1× against Diagnostics and Research's median of 4.5×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✓Revenue grew in the newest year40.6%Revenue up 40.6% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years77.4%77.4% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median77.4%77.4% a year against Diagnostics and Research's median of 3.6% (64 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$20 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability0 of 2
- ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.2×Current ratio 0.17 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-63.13Z-score -63.13 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year23.5%Diluted shares up 23.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
VolitionRx Limited: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 1.7+40.0%100% | 1.2+59.1%100% | 0.8+153%100% | 0.3+240%100% | 0.1+570%100% | 0.0−21.4%100% | 0.0—100% | — | — | — | |
| Research and development | 10−30.0%584% | 14−26.3%1168% | 20+27.5%2522% | 15r15+17.7%5004% | 13r16−10.4%14464% | 15+40.2%108195% | 10−5.0%60618% | 11+35.9%— | 8.0r8.9+1.5%— | 7.9r6.8—— | |
| Selling and marketing | 3.9−26.9%227% | 5.4−21.6%435% | 6.8+4.1%883% | 6.6+76.6%2146% | 3.7r4.1+247%4136% | 1.1+11.1%7991% | 1.0−17.4%5649% | 1.2+39.8%— | 0.8r0.8+141%— | 0.3—— | |
| General and administrative | 9.5+11.5%548% | 8.5−18.1%688% | 10+1.9%1337% | 10r11−12.8%3322% | 12r8.8+107%12969% | 5.7+19.5%42091% | 4.7−18.7%27673% | 5.8−0.2%— | 5.8r5.4+39.6%— | 4.2r0.7—— | |
| Operating expenses | 23−17.0%1358% | 28−23.1%2291% | 37+14.6%4742% | 32+12.9%10472% | 28+33.7%31569% | 21+32.4%158276% | 16−10.3%93940% | 18+21.8%— | 15r15+18.2%— | 12r12—— | |
| Operating income | −22—−1258% | −27—−2191% | −36—−4642% | −32—−10372% | −28—−31469% | −21—−158176% | −16—−93840% | −18—— | −15r−15—— | −12r−12—— | |
| Interest expense and finance costs | — | — | — | — | 0.2+20.0%173% | 0.1+2.5%966% | 0.1r−0.1—740% | −0.1r0.1−252%— | 0.1+259%— | 0.0—— | |
| Other non-operating income (expense) | −1.8—−102% | −0.2−175%−18.9% | 0.3−73.7%40.1% | 1.2−12.0%386% | 1.3+58.3%1492% | 0.8—6317% | −0.1—−328% | −0.1—— | — | — | |
| Net income including minority interests | −24—−1361% | −27—−2210% | −36—−4602% | — | −27—−29977% | −20—−151860% | −16—−94169% | −18—— | — | — | |
| Minority interests' share of net income | — | −0.3—−23.5% | −0.4r0.4−209%−46.2% | 0.3—108% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −23—−1352% | −27r−27—−2186% | −36—−4602% | −31—−9987% | −27—−29977% | −20—−151860% | −16—−94169% | −18—— | −15—— | −12—— | |
| Earnings per share, basic | — | — | — | — | -0.51—— | -0.45—— | -0.41—— | -0.57—— | -0.56—— | -0.52—— | |
| Earnings per share, diluted | — | -0.31—— | -0.50—— | — | -0.51—— | -0.45—— | -0.41—— | -0.57—— | -0.56—— | -0.52—— | |
| Shares, weighted average (diluted) | 107+23.5%— | 87+21.5%— | 71—— | — | 53+16.3%— | 45+15.6%— | 39+24.8%— | 31+18.9%— | 26+14.5%— | 23—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.1−65.8%16.2% | 3.3−84.3%34.7% | 21+90.8%74.2% | 11−47.2%59.4% | 21+5.8%74.9% | 19+14.6%74.4% | 17+26.4%79.7% | 13+32.7%76.8% | 10−53.3%69.2% | 22—87.7% | |
| Receivables | 0.3+187%4.6% | 0.1−54.4%1.2% | 0.2+234%0.9% | 0.1+480%0.4% | 0.0+75.8%0.0% | 0.0—0.0% | 0—0.0% | — | — | — | |
| Other current assets | 0.2−43.9%2.8% | 0.3−4.7%3.7% | 0.4−19.5%1.3% | 0.4−43.1%2.4% | 0.8+36.4%2.9% | 0.6+78.8%2.2% | 0.3+40.4%1.5% | 0.2+13.6%1.3% | 0.2+21.2%1.4% | 0.2—0.7% | |
| Current assets | 2.1−49.2%29.9% | 4.1−81.4%43.2% | 22+79.5%78.2% | 12−44.6%66.5% | 22+8.1%80.0% | 20+15.8%77.7% | 18+26.3%82.5% | 14+31.6%79.5% | 11−52.0%72.3% | 22—89.0% | |
| Property, plant and equipment | 4.0−9.1%58.4% | 4.4−19.8%47.1% | 5.5+2.4%19.8% | 5.4+9.8%29.5% | 4.9−5.0%17.9% | 5.2+73.5%19.8% | 3.0−4.4%14.0% | 3.1−10.4%17.8% | 3.5+64.3%23.8% | 2.1—8.6% | |
| Right-of-use (leased) assets | 0.5−17.3%7.2% | 0.6+9.2%6.4% | 0.5−11.3%2.0% | 0.6+61.5%3.4% | 0.4+17.6%1.4% | 0.3−14.5%1.2% | 0.4—1.8% | — | — | — | |
| Other intangible assets | 0.3+0.9%4.6% | 0.3+1214%3.3% | 0.0−78.4%0.1% | 0.1−49.0%0.6% | 0.2−32.6%0.8% | 0.3−13.6%1.2% | 0.4−20.3%1.7% | 0.5−19.0%2.7% | 0.6−4.3%3.9% | 0.6—2.4% | |
| Total assets | 6.9−26.6%100% | 9.4−66.4%100% | 28+52.8%100% | 18−33.4%100% | 27+5.1%100% | 26+22.8%100% | 21+21.7%100% | 17+19.6%100% | 15−40.9%100% | 25—100% | |
| Accounts payable | 2.9+5.5%42.3% | 2.8−13.9%29.4% | 3.2+5.5%11.5% | 3.0+97.3%16.6% | 1.5+0.2%5.6% | 1.5+145%5.9% | 0.6−22.3%2.9% | 0.8+129%4.6% | 0.4+25.1%2.4% | 0.3—1.1% | |
| Debt due within a year | 0.9+3.5%12.9% | 0.9−28.7%9.2% | 1.2+13.2%4.3% | 1.1+33.7%5.8% | 0.8−5.2%2.9% | 0.8+29.9%3.2% | 0.6+55.5%3.0% | 0.4−6.2%2.4% | 0.4+1348%3.0% | 0.0—0.1% | |
| Current liabilities | 12+57.0%177% | 7.8−12.9%82.9% | 8.9r32−48.6%32.0% | 17+167%95.0% | 6.5+4.5%23.7% | 6.2+61.6%23.8% | 3.9+65.4%18.1% | 2.3+1.9%13.3% | 2.3+12.6%15.7% | 2.0—8.2% | |
| Long-term debt | 5.8+47.2%84.3% | 4.0+9.0%42.1% | 3.6+30.4%13.0% | 2.8+22.4%15.2% | 2.3−12.9%8.3% | 2.6+18.7%10.0% | 2.2+10.6%10.3% | 2.0+51.1%11.3% | 1.3+204%9.0% | 0.4—1.7% | |
| Lease liabilities (non-current) | 0.3−32.7%4.0% | 0.4+8.6%4.4% | 0.4−5.5%1.4% | 0.4+84.1%2.2% | 0.2r0.2+21.0%0.8% | 0.2r0.2+36.2%0.7% | 0.1—0.6% | — | — | — | |
| Non-current liabilities | 30+9.2%439% | 28+474%295% | 4.8+19.6%17.3% | 4.0—22.1% | — | — | — | 3.0—17.2% | — | — | |
| Total liabilities | 42+19.7%616% | 36−3.2%378% | 37+71.1%131% | 21+119%117% | 9.8−0.9%35.5% | 9.9+39.0%37.7% | 7.1+32.6%33.3% | 5.3+14.6%30.6% | 4.7+31.2%31.9% | 3.6—14.4% | |
| Retained earnings | −253—−3665% | −230—−2442% | −203—−725% | −167—−914% | −137—−498% | −110—−421% | −90—−422% | −74—−422% | −56—−381% | −41—−166% | |
| Shareholders' equity | −34—−496% | −25—−265% | −7.8—−27.9% | −2.6r−3.1−115%−14.1% | 18r18+8.8%64.5% | 16+14.8%62.3% | 14+17.0%66.7% | 12+21.9%69.4% | 10.0−53.0%68.1% | 21—85.6% | |
| Minority interests | −1.3—−19.5% | −1.2—−12.8% | −0.9—−3.3% | −0.6—−3.0% | −0.2—−0.8% | — | — | — | — | — | |
| Total equity | −36—−516% | −26—−278% | −8.7—−31.2% | −3.1−118%−17.1% | 18+8.8%64.5% | 16r16+14.8%62.3% | 14—66.7% | — | — | — | |
| Total liabilities and equity | 6.9−26.6%100% | 9.4−66.4%100% | 28+52.8%100% | 18−33.4%100% | 27+5.1%100% | 26+22.8%100% | 21+21.7%100% | 17+19.6%100% | 15−40.9%100% | 25—100% | |
| Shares outstanding | 6.3r126−93.5%— | 96+17.3%— | 82+41.5%— | 58+7.6%— | 54+10.6%— | 49+18.2%— | 41+16.4%— | 35+33.2%— | 27+1.5%— | 26—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.0−11.6%56.9% | 1.1−3.4%90.2% | 1.2+23.1%149% | 0.9−1.0%306% | 0.9+32.0%1050% | 0.7+5.8%5332% | 0.7+6.4%3959% | 0.6+20.5%— | 0.5+70.7%— | 0.3—— | |
| Share-based compensation | 1.7+37.1%101% | 1.3−44.6%103% | 2.3−26.5%295% | 3.1r0+27.1%1017% | 2.5+76.1%2722% | 1.4−4.6%10359% | 1.5−43.2%8532% | 2.6+5.5%— | 2.4+45.1%— | 1.7—— | |
| Cash from operating activities | −20—−1139% | −26—−2099% | −18—−2330% | −15—−4986% | −21—−23162% | −16—−122566% | −13—−74517% | −15—— | −12—— | −8.9r−9.1—— | |
| Capital expenditure | −0.1—−5.2% | −0.3—−22.5% | −1.1—−140% | −1.6—−512% | −1.0—−1081% | −1.9—−14450% | −0.5r−0.5—−2991% | −0.3r−0.3—— | −1.4—— | −0.4—— | |
| Intangible assets bought | 0—0.0% | −0.3—−24.0% | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −0.1—−5.2% | −0.6—−46.5% | −1.1—−140% | −1.6—−512% | −1.0—−1081% | −1.6—−12266% | −0.5—−2991% | −0.3—— | −1.4—— | −0.4—— | |
| Debt issued | 2.0+44.7%115% | 1.4−26.2%111% | 1.9+21.8%239% | 1.5—497% | — | — | 0.8−27.7%4902% | 1.2−3.5%— | 1.2—— | — | |
| Debt repaid | −0.9—−50.8% | −1.1—−88.2% | −1.0—−127% | −1.3—−414% | — | — | −0.4—−2053% | −0.4—— | — | — | |
| Shares issued | 11+30.0%647% | 8.6−69.7%697% | 28+321%3662% | 6.7−71.0%2199% | 23+9.5%25790% | 21+27.8%157794% | 17−3.8%97047% | 17+1627%— | 1.0−96.1%— | 25—— | |
| Shares bought back | — | 0—0.0% | −0.0—−4.1% | 0—0.0% | — | — | — | — | — | — | |
| Cash from financing activities | 17+97.4%990% | 8.7−70.1%702% | 29+318%3738% | 6.9−69.6%2264% | 23+10.8%25387% | 21+21.8%153509% | 17−5.8%99026% | 18+813%— | 2.0−92.2%— | 25r25—— | |
| Exchange-rate effect on cash | 0.5+54.5%30.8% | 0.3+1177%27.9% | 0.0−86.2%3.5% | 0.2+83.7%63.8% | 0.1—118% | −0.0—−225% | −0.1−137%−818% | 0.4+325%— | 0.1—— | −0.1—— | |
| Change in cash | −2.1—−124% | −17−277%−1416% | 9.9—1272% | −9.7−955%−3171% | 1.1−54.1%1262% | 2.5−30.0%18451% | 3.5+6.9%20700% | 3.3—— | −12−173%— | 16—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 3.4+134%100% | 1.6+157%100% | 0.4−2.0%100% | 1.0+300%100% | 0.4*+133%100% | 0.6+32.2%100% | 0.4+2.8%100% | 0.2+43.6%100% | 0.2*−21.4%100% | 0.5—100% | 0.4—100% | 0.2—100% | 0.2*—100% | |
| Research and development | 9.1−10.7%264% | 2.0−13.0%123% | 1.8−33.8%452% | 2.9+9.4%290% | 2.5*−4.6%552% | 2.3−34.2%364% | 2.7−26.8%669% | 2.6−43.7%1058% | 2.6*−43.1%1350% | 3.5—732% | 3.7—939% | 4.6—2699% | 4.5*—1862% | |
| Selling and marketing | 3.0−28.6%86.5% | 0.6−39.8%35.7% | 0.5−47.4%138% | 0.9−7.1%86.5% | 1.0*−20.0%224% | 1.0−9.0%153% | 1.0−24.7%257% | 0.9−45.2%372% | 1.3*−34.1%653% | 1.1—222% | 1.4—350% | 1.7—975% | 1.9*—778% | |
| General and administrative | 9.0−8.1%262% | 2.4−4.1%148% | 2.2−25.0%553% | 2.6+17.2%267% | 1.8*−15.9%402% | 2.5+36.8%396% | 2.9+28.8%723% | 2.2−0.5%911% | 2.1*−16.0%1113% | 1.8—383% | 2.3—577% | 2.3—1314% | 2.5*—1042% | |
| Operating expenses | 21−12.7%613% | 4.9−13.6%307% | 4.6−32.1%1142% | 6.3+9.8%643% | 5.3*−11.8%1178% | 5.7−9.7%913% | 6.7−9.2%1649% | 5.8−32.6%2341% | 6.0*−33.5%3117% | 6.3—1337% | 7.4—1866% | 8.6—4988% | 9.0*—3683% | |
| Operating income | −18—−513% | −3.3—−207% | −4.2—−1042% | −5.3—−543% | −4.8*—−1078% | −5.1—−813% | −6.3—−1549% | −5.5—−2241% | −5.8*—−3017% | −5.9—−1237% | −7.0—−1766% | −8.4—−4888% | −8.7*—−3583% | |
| Interest expense and finance costs | — | 0.1−0.7%8.8% | 0.7+500%186% | 0.1+30.2%12.8% | — | 0.1—22.9% | 0.1—30.3% | 0.1—39.2% | — | — | — | — | — | |
| Other non-operating income (expense) | −6.5—−188% | −0.5—−29.3% | −3.2—−792% | −1.4−3104%−138% | −1.5*—−332% | −0.3−239481%−49.2% | −0.0—−4.0% | 0.0—18.3% | −0.1*—−39.6% | 0.0—0.0% | −0.1—−17.6% | −0.1—−51.0% | −0.1*—−24.2% | |
| Net income including minority interests | −24—−700% | −3.8—−236% | −7.3—−1835% | −6.7—−681% | −6.3*—−1410% | −5.4—−862% | −6.3—−1553% | −5.5—−2223% | −5.9*—−3056% | −5.9—−1237% | −7.1—−1784% | −8.5—−4939% | −8.8*—−3607% | |
| Minority interests' share of net income | — | −0.0—−0.5% | 0.0—2.7% | −0.0—−3.9% | — | −0.0—−5.0% | −0.0−140%−7.4% | −0.1—−21.5% | −0.1*—−33.3% | −0.0—−9.9% | 0.1—18.9% | −0.1r0.1—−61.0% | −0.1r0.6*—−41.6% | |
| Net income attributable to shareholders | −24—−699% | −3.8—−235% | −7.3—−1838% | −6.7—−677% | −6.3*—−1403% | −5.4—−857% | −6.3—−1545% | −5.4—−2201% | −5.8r−6.1*—−3023% | −5.8r−5.9—−1227% | −7.0r−7.1—−1765% | −8.4r−8.5—−4878% | −8.8*—−3607% | |
| Earnings per share, diluted | — | -0.21—— | -0.85—— | -0.97—— | — | -0.99r-0.05—— | -1.22r-0.06—— | -1.12r-0.06—— | — | -0.07—— | -0.08—— | -0.10—— | — | |
| Shares, weighted average (diluted) | 19+249%— | 19+249%— | 9.2+78.4%— | 6.9+42.6%— | — | 5.4r108−93.8%— | 5.1r103−93.8%— | 4.8r97−94.1%— | — | 88—— | 83—— | 82—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.4—33.3% | 2.4+1100%33.3% | 2.8+21.7%33.7% | 3.1+19.3%34.3% | 1.1−65.8%16.2% | 0.2−96.3%3.1% | 2.3−61.7%26.4% | 2.6−77.9%30.5% | 3.3−84.3%34.7% | 5.4—42.7% | 6.0—45.9% | 12—60.6% | 21—74.2% | |
| Receivables | 0.2—2.5% | 0.2−40.9%2.5% | 0.3+46.3%3.3% | 0.3+34.3%2.8% | 0.3+187%4.6% | 0.3−1.1%4.8% | 0.2+14.0%2.2% | 0.2+40.7%2.2% | 0.1−54.4%1.2% | 0.3—2.5% | 0.2—1.3% | 0.1—0.7% | 0.2—0.9% | |
| Other current assets | 0.3—4.2% | 0.3−16.0%4.2% | 0.3−2.2%4.0% | 0.3+13.9%3.2% | 0.2−43.9%2.8% | 0.4−5.4%5.6% | 0.3−2.2%3.9% | 0.3−45.6%3.0% | 0.3−4.7%3.7% | 0.4—3.0% | 0.4—2.7% | 0.5—2.4% | 0.4—1.3% | |
| Current assets | 3.2—44.8% | 3.2+142%44.8% | 4.1+25.4%49.3% | 4.5+37.1%50.0% | 2.1−49.2%29.9% | 1.3−80.4%20.7% | 3.3−55.6%37.5% | 3.3−75.5%38.7% | 4.1−81.4%43.2% | 6.8—53.6% | 7.3—56.2% | 13—69.3% | 22—78.2% | |
| Property, plant and equipment | 3.4—47.4% | 3.4−19.6%47.4% | 3.6−20.8%42.9% | 3.8−13.3%41.7% | 4.0−9.1%58.4% | 4.2−13.5%65.8% | 4.5−7.8%51.7% | 4.3−16.1%51.0% | 4.4−19.8%47.1% | 4.9—38.7% | 4.9—37.3% | 5.2—26.7% | 5.5—19.8% | |
| Right-of-use (leased) assets | 0.3—3.7% | 0.3−53.3%3.7% | 0.3−46.6%4.1% | 0.4−23.3%4.8% | 0.5−17.3%7.2% | 0.6−10.0%8.9% | 0.6+24.0%7.3% | 0.6−1.5%6.6% | 0.6+9.2%6.4% | 0.6—5.0% | 0.5—3.9% | 0.6—2.9% | 0.5—2.0% | |
| Other intangible assets | 0.3—4.1% | 0.3−1.3%4.1% | 0.3−0.4%3.7% | 0.3+0.6%3.5% | 0.3+0.9%4.6% | 0.3−10.2%4.7% | 0.3−7.8%3.5% | 0.3+47.4%3.7% | 0.3+1214%3.3% | 0.3—2.6% | 0.3—2.5% | 0.2—1.1% | 0.0—0.1% | |
| Total assets | 7.2—100% | 7.2+11.7%100% | 8.3−4.6%100% | 9.0+6.1%100% | 6.9−26.6%100% | 6.4−49.1%100% | 8.7−33.4%100% | 8.5−56.2%100% | 9.4−66.4%100% | 13—100% | 13—100% | 19—100% | 28—100% | |
| Accounts payable | 3.0—42.0% | 3.0−2.9%42.0% | 3.6+51.6%42.9% | 3.7+23.5%41.2% | 2.9+5.5%42.3% | 3.1+25.3%48.3% | 2.4−29.8%27.0% | 3.0−14.6%35.4% | 2.8−13.9%29.4% | 2.5—19.6% | 3.3—25.6% | 3.5—18.2% | 3.2—11.5% | |
| Debt due within a year | 2.0—27.6% | 2.0+118%27.6% | 1.1+5.2%12.9% | 0.9+9.0%10.4% | 0.9+3.5%12.9% | 0.9−5.3%14.2% | 1.0−2.5%11.7% | 0.9−25.0%10.1% | 0.9−28.7%9.2% | 1.0—7.6% | 1.0—8.0% | 1.1—5.9% | 1.2—4.3% | |
| Current liabilities | 9.9—137% | 9.9−13.4%137% | 13+46.0%163% | 14+64.0%150% | 12+57.0%177% | 11−62.3%177% | 9.2−70.2%106% | 8.3−73.7%97.1% | 7.8−12.9%82.9% | 30—239% | 31—237% | 31—162% | 8.9r32—32.0% | |
| Long-term debt | 4.7—65.6% | 4.7−15.1%65.6% | 6.0+3.6%72.1% | 6.4+14.8%70.3% | 5.8+47.2%84.3% | 5.6+45.0%86.3% | 5.8+49.3%66.3% | 5.5+64.0%64.9% | 4.0+9.0%42.1% | 3.8—30.3% | 3.9—29.6% | 3.4—17.4% | 3.6—13.0% | |
| Lease liabilities (non-current) | 0.1—1.6% | 0.1−67.0%1.6% | 0.2−62.2%1.9% | 0.2−43.5%2.3% | 0.3−32.7%4.0% | 0.4−21.6%5.4% | 0.4+18.9%4.8% | 0.4−6.8%4.3% | 0.4+8.6%4.4% | 0.4—3.5% | 0.4—2.7% | 0.4—2.0% | 0.4—1.4% | |
| Non-current liabilities | 25—344% | 25−19.9%344% | 28−12.9%341% | 29−1.5%319% | 30+9.2%439% | 31+514%480% | 33+553%374% | 29+542%344% | 28+474%295% | 5.0—39.8% | 5.0—38.2% | 4.6—23.5% | 4.8—17.3% | |
| Total liabilities | 35—482% | 35−18.2%482% | 42+0.1%504% | 42+12.9%469% | 42+19.7%616% | 42+20.0%657% | 42+16.2%480% | 38+4.1%441% | 36−3.2%378% | 35—279% | 36—275% | 36—186% | 37—131% | |
| Retained earnings | −271—−3766% | −271—−3766% | −267—−3221% | −260—−2872% | −253—−3665% | −247—−3824% | −241—−2771% | −235—−2758% | −230—−2442% | −224—−1765% | −218—−1668% | −211—−1085% | −203—−725% | |
| Shareholders' equity | −26—−363% | −26—−363% | −32—−387% | −32—−354% | −34—−496% | −35—−537% | −32—−365% | −28—−326% | −25—−265% | −22—−170% | −22—−167% | −16—−80.3% | −7.8—−27.9% | |
| Minority interests | −1.4—−19.2% | −1.4—−19.2% | −1.4—−16.6% | −1.4—−15.3% | −1.3—−19.5% | −1.3—−20.4% | −1.3—−14.7% | −1.3—−14.7% | −1.2—−12.8% | −1.1—−9.0% | −1.1—−8.3% | −1.0—−5.2% | −0.9—−3.3% | |
| Total equity | −27—−382% | −27—−382% | −34—−404% | −33—−369% | −36—−516% | −36—−557% | −33—−380% | −29—−341% | −26—−278% | −23—−179% | −23—−175% | −17—−85.5% | −8.7—−31.2% | |
| Total liabilities and equity | 7.2—100% | 7.2+11.7%100% | 8.3−4.6%100% | 9.0+6.1%100% | 6.9−26.6%100% | 6.4−49.1%100% | 8.7−33.4%100% | 8.5−56.2%100% | 9.4−66.4%100% | 13—100% | 13—100% | 19—100% | 28—100% | |
| Shares outstanding | 33—— | 33−70.1%— | 12−88.4%— | 7.9−92.1%— | 6.3r126−93.5%— | 110+18.6%— | 104+25.4%— | 101+22.7%— | 96+17.3%— | 92—— | 83—— | 82—— | 82—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.8−23.2%23.4% | 0.2*−28.0%11.1% | 0.2*−25.6%47.2% | 0.2−17.7%21.1% | 0.2*−21.9%51.6% | 0.2*−12.9%39.6% | 0.3*−6.2%62.1% | 0.3−4.3%102% | 0.3*−0.3%154% | 0.3*—60.1% | 0.3*—68.0% | 0.3—153% | 0.3*—122% | |
| Share-based compensation | — | 0.2*−69.3%11.6% | 0.2*−70.7%59.7% | 0.2−50.2%22.8% | — | 0.6*+88.3%97.1% | 0.8*+290%200% | 0.5+9.8%183% | 0.3*−30.1%170% | 0.3—68.2% | 0.2—52.6% | 0.4—240% | 0.5*—191% | |
| Cash from operating activities | −21—−596% | −4.6*—−284% | −5.2*—−1294% | −5.3—−536% | −5.5*—−1229% | −3.6*—−579% | −6.3*—−1540% | −4.3—−1744% | −5.4*−184%−2834% | −5.4*—−1135% | −6.7*—−1701% | −8.3—−4863% | 6.4*—2643% | |
| Capital expenditure | −0.1—−2.0% | −0.0*—−2.9% | −0.0*—−0.4% | −0.0—−0.9% | −0.0*—−2.5% | 0*—0.0% | −0.1*—−18.9% | −0.0—−0.7% | −0.1*—−37.9% | −0.1*—−28.8% | −0.0*—−9.9% | −0.0—−16.8% | −0.3*—−127% | |
| Intangible assets bought | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | −0.1*—−65.4% | 0*—0.0% | — | — | — | |
| Cash from investing activities | −0.1—−2.0% | −0.0*—−2.9% | −0.0*—−0.4% | −0.0—−0.9% | −0.0*—−2.5% | 0*—0.0% | −0.1*—−18.9% | −0.0—−0.7% | −0.2*—−103% | −0.1*—−28.8% | −0.2*—−40.5% | −0.1—−45.9% | −0.3*—−127% | |
| Debt issued | 1.4−37.2%39.9% | 0*—0.0% | 0*—0.0% | 1.0−38.7%97.7% | 0.4*−33.2%91.7% | 0*—0.0% | 0*−100%0.0% | 1.6—637% | 0.6*−62.5%320% | 0*—0.0% | 0.8*—191% | 0—0.0% | 1.6*—671% | |
| Debt repaid | −0.9—−26.2% | −0.3*—−18.4% | −0.2*—−45.3% | −0.2—−25.0% | −0.2*—−40.3% | −0.3*—−45.5% | −0.2*—−39.4% | −0.3—−102% | −0.3*—−134% | −0.3*—−63.4% | −0.3*—−81.0% | −0.2—−123% | −0.3*—−123% | |
| Shares issued | 22+247%652% | 5.1*+156%319% | 5.4*+8588%1363% | 5.2+117%525% | 6.7*+231%1502% | 2.0*−66.3%320% | 0.1*−89.4%15.4% | 2.4+15057%968% | 2.0*−21.8%1057% | 6.0*—1256% | 0.6*—149% | 0.0—9.2% | 2.6r2.5*—1063% | |
| Shares bought back | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Cash from financing activities | 23+74.6%670% | 4.3*+171%269% | 5.0*−12.2%1249% | 7.6+108%773% | 6.2*+169%1377% | 1.6*−71.4%255% | 5.7*+482%1394% | 3.7—1488% | 2.3*−39.3%1195% | 5.6*—1181% | 1.0*—246% | −0.2—−122% | 3.8*—1545% | |
| Exchange-rate effect on cash | −0.3−124%−10.1% | −0.1*—−8.7% | −0.1*−140%−32.5% | −0.3—−34.6% | 0.3*−77.8%59.2% | −0.0*—−4.1% | 0.3*+123%79.9% | −0.0—−12.7% | 1.2*+10026%621% | −0.7*—−140% | 0.1*—36.8% | −0.3—−191% | 0.0*—4.8% | |
| Change in cash | 2.2—62.6% | −0.4*—−26.9% | −0.3*—−78.2% | 2.0—202% | 0.9*—205% | −2.1*—−328% | −0.3*—−84.7% | −0.7—−270% | −2.1*−122%−1122% | −0.6*—−123% | −5.8*—−1459% | −9.0—−5222% | 9.9*—4067% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at VolitionRx Limited#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 3 · Material agreement 9 · Unregistered share sale 8 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Unregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K/A | |
| Results announced | 8-K | |
| Material agreement | 8-K/A | |
| Material agreement | 8-K | |
| Material agreementResults announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2025 | $23 M | Private placement after listing | $10 to $50 million | 1 | debt, options | SEC |
| Aug 2018 | $24 M | Private placement after listing | $10 to $50 million | 1 | equity, options | SEC |
| Sep 2014 | $1 M | No. 3 | Under $2 million | 7 | equity | SEC |
| Feb 2014 | $3 M | No. 2 | $2 to $10 million | 24 | equity, options | SEC |
| Apr 2012 | $1 M | No. 1 | Under $2 million | 33 | equity, options | SEC |
| Oct 2011 | $2 M | Issued in a merger or acquisition | Under $2 million | 38 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How VolitionRx Limited compares in Diagnostics and Research
- Market cap$7 M · higher than 9% of 110
- Revenue$2 M · higher than 7% of 123
- Net margin-699.7% · higher than 0% of 112
- Revenue growth40.6% · higher than 90% of 89
- Price / sales2.1× · lower than 69% of 85
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| VolitionRx Limited🇺🇸 | $7 M | — | -699.7% | +40.6% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at VolitionRx Limited? Verify and update this profile — free
Show VolitionRx Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.